Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02454907 · ClinicalTrials.gov registry record · NA

The Use of Technology to Improve MS Clinical Trials and Patient Care

A NA study of Multiple Sclerosis, sponsored by Johns Hopkins University.

Active
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT02454907: Active NA study of Multiple Sclerosis, sponsored by Johns Hopkins University.

NCT02454907 is a NA study of Multiple Sclerosis that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 150 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02454907, a NA study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Johns Hopkins University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numbness, weakness, visual problems, or other symptoms. If a person with MS has new symptoms that are concerning to them, their doctor may want to see them in the office in order to confirm that these symptoms are due to a true "relapse" of activity before starting relapse treatment. This requirement can be frustrating for patients, who may have to take time off from work or travel long distances for such unexpected doctors' visits. In this study, the investigators will use input from patients with MS and MS physicians to create a relapse questionnaire that can be used to confirm a relapse has occurred. The investigators will also evaluate if having a more direct line of communication with the provider's office improves overall patient care and satisfaction.

Primary Outcome

The primary and secondary outcomes for this study are blinded.

Conditions Studied

Interventions

  • OTHER Communication with the clinic

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2018-07-31
Est. Completion 2026-05-31
Phase NA
Johns Hopkins University

1,448 total trials

What the registry record for NCT02454907 still lists

NCT02454907 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Communication with the clinic is the first listed.

NCT02454907 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02454907 about?

NCT02454907 is a clinical study titled "The Use of Technology to Improve MS Clinical Trials and Patient Care". Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numbness, weakness, visual problems, or other symptoms. If a person with MS has new symptoms that are concerning to them, their doctor may want to see them in the office in order to ...

What is the current status of trial NCT02454907?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2018-07-31. Estimated completion is 2026-05-31.

What conditions does trial NCT02454907 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT02454907?

The interventions under investigation include: Communication with the clinic (OTHER).

Who is sponsoring clinical trial NCT02454907?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02454907 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02454907's enrollment target sits among peer trials

150 93rd of 315 higher than 219 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02454907, the US trial registry maintained by the National Library of Medicine. NCT02454907 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.